Our data showing the concomitant loss of pHH3+ cells and gain in CC3+ cells in Abraxane/ABT-263 co-microinjected regions is consistent with the proposal that inhibition of BCL2/BCLxl drives cells towards the apoptotic fate ultimately leading to tumor regression. This evidence concerns the gene BCL2 and neoplasm.